Skip to main content
Premium Trial:

Request an Annual Quote

Short Reads: Sep 1, 2001 (rev. 1)

Premium

Extra, extra! Led by the Public Library of Science Initiative, more than 25,000 scientists have pledged their support for the boycott of many scientific journals. PLSI plans to begin putting out its own journals this month, providing an alternative outlet to publications that refuse to deposit their articles in a free online environment. At press time, only Genome Research and PubMedCentral had agreed to scientists’ demands that all articles be made freely accessible.

 

Nonprofit corporation Genome Canada will invest up to C$165 million to fund a second wave of genomics experiments. Researchers across Canada will compete for the funding for projects on ethical, environmental, legal, and societal issues related to genomics.

 

Eye on alliances: Inpharmatica signed a two-year deal potentially worth $20 million with Geneva-based Serono to find novel protein targets. DeCode and Roche allied in a five-year program to develop and market DNA-based diagnostics for major diseases. Exelixis and Bristol-Myers Squibb penned a $200 million deal to work on cancer-related target validation. DNAPrint expands its work by partnering with Malaysian pharmacogenomics company DNAPro and establishing subsidiary DNAPrint Genomics, which aims to design personalized medicine products for Southeast Asian populations. GeneTrove, the functional genomics division of Isis Pharmaceuticals, will work with Celera Genomics to find functions of 200 novel genes. Genomic Solutions collaborates with NuTec Sciences to design and market a new software product.

 

The Ontario Centre for Genomic Computing will expand over the next three years, thanks to a $25 million deal with SGI financed by The Hospital for Sick Children and the Ontario Research and Development Challenge Fund.

 

Moving toward one giant genomics company: Deltagen agreed to acquire functional proteomics company Arcaris for roughly $7.7 million; Lexicon Genetics acquired chemistry-oriented Coelecanth for $32 million; Cellomics is set to buy Momentum Healthcare, which works with drug discovery software; and Genomic Solutions of Ann Arbor, Mich., was in talks to acquire New York firm ProteoMetrics.

 

The National Institute for Standards and Technology awarded bioinformatics company Incogen a grant worth $2 million to work on XML and web services technology for better access to different genomics tools.

 

Sun’s trying to keep its name out there. The company recently launched CB-SIG, its special interest group for computational biology. Most recently, it named the Delaware Bioinformatics Institute and the Beijing Genomics Institute as Sun Centers of Excellence.

 

Lincoln Stein may need to clone himself if he doesn''t want to play favorites to dueling computer vendors. The Cold Spring Harbor bioinformaticist is slated to speak on a proteomics panel at a meeting hosted by Compaq and the Whitehead Institute in Cambridge this month. But, according to Sun''s agenda for a simultaneous meeting on post-genomic computing challenges, Stein will be speaking in Durham, NC, that day. Seems he could use Tony White''s jet privileges.

 

A desktop DNA accelerator? That’s what Compaq and Time Logic say they’ll demo at GSAC this year — a people’s version of Time Logic’s DeCypher, My DeCypher, available at a fraction of the cost and running on Compaq’s DeskPro Workstation 300.

 

Here at GT, we’re regularly entertained by new and creative company names. The latest contender in the ongoing “-omics” battle is Nanogen and Aventis Research & Technology’s Frankfurt-based lovechild, Nanogen Recognomics. Meanwhile, suspicion abounds over new Gene Logic spinoff MetriGenix, which was announced on the heels of Genometrix’s closing. Genometrix, MetriGenix — coincidence?

 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.